Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Zong-Liang Lu"'
Publikováno v:
journal of nutritional oncology. 4:74-84
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::53c87121c88bba9160e02fd6211955b2
https://doi.org/10.34175/jno201902004
https://doi.org/10.34175/jno201902004
Autor:
Xue Hai Yu, Jian-Jun Li, Wen Rong Kou, Yu Cheng Zhao, Zuo Chen, Roberto Bolli, Yang Feng Wu, Zong Liang Lu
Publikováno v:
International Journal of Cardiology. 154:362-365
sudden cardiac death in childrenwith the congenital long-QT syndrome. Circulation 2008;117:2184–91. [9] JonsC,MossAJ,Goldenberg I, et al. Risk of fatal arrhythmicevents in longQTsyndrome patients after syncope. J Am Coll Cardiol 2010;55:783–8. [1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8fc0b27628bbf6c2bd3161375e12b98e
https://doi.org/10.1016/j.ijcard.2011.11.005
https://doi.org/10.1016/j.ijcard.2011.11.005
Autor:
Jian-Jun, Li, Zong-Liang, Lu, Wen-Rong, Kou, Zuo, Chen, Yang-Feng, Wu, Xue-Hai, Yu, Yu-Cheng, Zhao, S, Wang
Publikováno v:
Annals of Medicine. 42:231-240
The lowering of cholesterol concentrations in individuals at high risk for cardiovascular disease improves clinical outcome. Xuezhikang has a marked impact on lipids.In this randomized, double-blinded, placebo-controlled, parallel-group clinical tria
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ac72f19ec7360ab79f5e2057641c976
https://doi.org/10.3109/07853891003652534
https://doi.org/10.3109/07853891003652534
Publikováno v:
Journal of the American Geriatrics Society. 55:1015-1022
OBJECTIVES: To evaluate whether lipid-lowering therapy with xuezhikang reduces the risk of coronary events and total mortality in patients with coronary heart disease (CHD) aged 65 and older. DESIGN: Subgroup analysis of the China Coronary Secondary
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5041419c75a8268064f641a60d5c3944
https://doi.org/10.1111/j.1532-5415.2007.01230.x
https://doi.org/10.1111/j.1532-5415.2007.01230.x
Autor:
Wen-Qi Chen, Xiao-Dong Zhu, Xiu-Jie Liu, Yunzhong Liu, Rong-Fang Shi, Sheng-Ting Li, Qing-Wen Wu, Zong-Liang Lu
Publikováno v:
Journal of Nuclear Cardiology. 3:457-463
Assessment of viable myocardium in territories of hypoperfused myocardium is important for predicting functional recovery after revascularization. This study was designed to evaluate quantitative analysis of 99mTc-labeled 2-methoxyisobutyl isonitrile
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::178a32ace684d310955ce4f072810b03
https://doi.org/10.1016/s1071-3581(96)90055-0
https://doi.org/10.1016/s1071-3581(96)90055-0
Autor:
Yang Yj, Rong-Fang Shi, Lu Yz, Xiao-Dong Zhu, Zong-Liang Lu, Xiu-Jie Liu, Sheng-Ting Li, Lu F, Qing-Wen Wu, Chen Wq
Publikováno v:
Annals of Nuclear Medicine. 10:13-18
Tc-99m MIBI myocardial SPECT has shown promise for evaluation of coronary artery disease. But its role in predicting myocardial viability is still under investigation. The purpose of this study was to evaluate the value of Tc-99m MIBI myocardial SPEC
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fa505975b96d0e111c029eacf91fd88b
https://doi.org/10.1007/bf03165049
https://doi.org/10.1007/bf03165049
Autor:
Jian-Jun, Li, Zong-Liang, Lu, Wen-Rong, Kou, Zuo, Chen, Yang-Feng, Wu, Xue-Hai, Yu, Yu-Cheng, Zhao, S, Wang
Publikováno v:
Clinical and experimental hypertension (New York, N.Y. : 1993). 32(8)
Several previous trials from Western population studies have showed that statins may help reduce blood pressure (BP). However, randomized clinical data is limited. Xuezhikang, a partially extract of red yeast rice, contains a family of naturally occu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16db573b9b995279a874f82a20956854
https://pubmed.ncbi.nlm.nih.gov/21091365
https://pubmed.ncbi.nlm.nih.gov/21091365
Publikováno v:
Journal of the American Geriatrics Society. 55(7)
To evaluate whether lipid-lowering therapy with xuezhikang reduces the risk of coronary events and total mortality in patients with coronary heart disease (CHD) aged 65 and older.Subgroup analysis of the China Coronary Secondary Prevention Study, a r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a034284732459506859c48b1c73c7af7
https://pubmed.ncbi.nlm.nih.gov/17608873
https://pubmed.ncbi.nlm.nih.gov/17608873
Autor:
Yang-feng Wu, Zhi-hong Wu, Yu-cheng Zhao, Hui-jun Ye, Zong-liang Lu, Xue-hai Yu, Zuo Chen, Shui-ping Zhao, Ling Liu, Bao-min Du
Publikováno v:
Journal of cardiovascular pharmacology. 49(2)
Lipid-lowering therapy has been proven to reduce macrovascular complications of type 2 diabetes. Xuezhikang is an extract of cholestin and has a markedly modulating effect on lipids, but the effect of xuezhikang on reducing coronary events in diabeti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::505a1389f0d3fc449eae38c856968a64
https://pubmed.ncbi.nlm.nih.gov/17312447
https://pubmed.ncbi.nlm.nih.gov/17312447
Publikováno v:
Zhonghua xin xue guan bing za zhi. 34(10)
To evaluate whether lipid-lowering therapy with Xuezhikang can reduce the risk of cardiac events and total mortality in coronary heart disease (CHD) patients with or without hypertension.In this random, double-blinded, placebo controlled clinical tri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a820bde04726255477b6c6d5abf8fcaa
https://pubmed.ncbi.nlm.nih.gov/17217713
https://pubmed.ncbi.nlm.nih.gov/17217713